Santhera Board Proposes the Election of Klaus Schollmeier to the Company's Board
Santhera Pharmaceuticals announced that its Board of Directors has decided to propose the appointment of Dr Klaus Schollmeier, the Company's Chief Executive Officer (CEO), to the Board. This appointment would be for a term of three years. Dr Schollmeier's appointment to the Board is subject to the approval at the upcoming Shareholder's Meeting, scheduled for April 23, 2007, in Basel, Switzerland.
Michael Lytton, Chairman of the Board of Directors, commented: "Klaus Schollmeier has been CEO of Santhera since its inception in 2004 and, previously, one of its predecessor companies, Graffinity, since 2003. Klaus Schollmeier has been a main driving force behind the Company's considerable success. Over this period, Santhera has developed an exciting portfolio of neuromuscular drug candidates and has raised close to CHF 190 million in new funds from both private and public investors. The Board believes that, with the addition of Klaus Schollmeier to the Company's Board, Santhera's decision making processes can become even more effective and efficient ensuring high quality and direct information flow between the Board and the Executive Management."
Other news from the department people
